113 related articles for article (PubMed ID: 22488744)
21. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
[TBL] [Abstract][Full Text] [Related]
22. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
[TBL] [Abstract][Full Text] [Related]
23. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
24. Esophageal Ulcer in a Lung Cancer Patient. Crizotinib-induced Esophageal Injury.
Sawada T; Maeno K; Joh T
Gastroenterology; 2015 Aug; 149(2):e6-7. PubMed ID: 26123560
[No Abstract] [Full Text] [Related]
25. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.
Yamazaki S; Vicini P; Shen Z; Zou HY; Lee J; Li Q; Christensen JG; Smith BJ; Shetty B
J Pharmacol Exp Ther; 2012 Mar; 340(3):549-57. PubMed ID: 22129595
[TBL] [Abstract][Full Text] [Related]
26. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy.
Sarosdy MF
Cancer; 2007 Feb; 109(3):536-41. PubMed ID: 17183557
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
28. A study of the endocrine manifestations of hepatic cirrhosis.
Baker HW; Burger HG; de Kretser DM; Dulmanis A; Hudson B; O'Connor S; Paulsen CA; Purcell N; Rennie GC; Seah CS; Taft HP; Wang C
Q J Med; 1976 Jan; 45(177):145-78. PubMed ID: 769039
[TBL] [Abstract][Full Text] [Related]
29. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
30. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
31. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK.
Sun HY; Ji FQ
Biochem Biophys Res Commun; 2012 Jun; 423(2):319-24. PubMed ID: 22659414
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
[TBL] [Abstract][Full Text] [Related]
33. Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
Ji Y; Zhang Z; Nie K; Lan K; Geng C; Liu S; Zhang L; Zhang Z; Sun L; Zou X
Chin Med J (Engl); 2014; 127(8):1600. PubMed ID: 24762619
[No Abstract] [Full Text] [Related]
34. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial?
Black AM; Day AG; Morales A
BJU Int; 2004 Nov; 94(7):1066-70. PubMed ID: 15541129
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism.
Citron JT; Ettinger B; Rubinoff H; Ettinger VM; Minkoff J; Hom F; Kan P; Alloo R
J Urol; 1996 Feb; 155(2):529-33. PubMed ID: 8558653
[TBL] [Abstract][Full Text] [Related]
36. Feedback inhibition of gonadotropins by testosterone in men with hypogonadotropic hypogonadism: comparison to the intact pituitary-testicular axis in primary hypogonadism.
Shimon I; Lubina A; Gorfine M; Ilany J
J Androl; 2006; 27(3):358-64. PubMed ID: 16474013
[TBL] [Abstract][Full Text] [Related]
37. Testosterone and gonadotropin levels in men with dementia.
Hogervorst E; Combrinck M; Smith AD
Neuro Endocrinol Lett; 2003; 24(3-4):203-8. PubMed ID: 14523358
[TBL] [Abstract][Full Text] [Related]
38. Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.
Zagars GK; Pollack A; von Eschenbach AC
Urology; 1997 Mar; 49(3):327-34. PubMed ID: 9123693
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
40. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]